A study of 105 breast cancer patients showed that IL-10 expression was higher in patients with higher ER negative and SBR classification; higher serum IL-6 levels were more common in triple negative breast cancer (TNBC) patients and used to monitor predictive therapeutic response4. Here, IL10 is linked to triple-negative breast carcinoma.